

20 October 2023

**Scancell Holdings plc**  
("Scancell" or the "Company")

**Update on Final Results**

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, provides the following update in relation to the publication of its results for the year ended 30 April 2023.

The Company's auditor, BDO LLP, has requested additional time to complete their standard audit due to unforeseen circumstances impacting the audit engagement team. Scancell's Board has been advised that the audit is substantially complete and has not been advised of any material audit issues.

Accordingly, the Company is targeting the publication of its audited financial results as soon as the auditor completes their final processes.

**-ENDS-**

**For further information, please contact:**

**Scancell Holdings plc**

+44 (0) 20 3709 5700

Professor Lindy Durrant, CEO  
Dr Jean-Michel Cosséry, Non-Executive Chairman

**Stifel Nicolaus Europe Limited** (Nominated Adviser and Joint Broker)

+44 (0) 20 7710 7600

Nicholas Moore/Samira Essebiyeva/William Palmer-Brown (Healthcare Investment Banking)

Nick Adams/Nick Harland (Corporate Broking)

**Panmure Gordon (UK) Limited** (Joint Broker)

+44 (0) 20 7886 2500

Freddy Crossley/Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

**ICR Consilium**

+44 (0) 20 3709 5700

Mary-Jane Elliott/Matthew Neal/Chris Welsh

[scancell@consilium-comms.com](mailto:scancell@consilium-comms.com)

**About Scancell**

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope<sup>®</sup> and ImmunoBody<sup>®</sup> for vaccines and GlyMab<sup>®</sup> and AvidiMab<sup>®</sup> for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the

vaccines (Moditope<sup>®</sup> and ImmunoBody<sup>®</sup>) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab<sup>®</sup>) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab<sup>®</sup>).

For further information about Scancell, please visit: <https://www.scancell.co.uk/>